Antibiotics versus placebo in adults with CT-confirmed uncomplicated acute appendicitis (APPAC III): randomized double-blind superiority trial.
Journal
The British journal of surgery
ISSN: 1365-2168
Titre abrégé: Br J Surg
Pays: England
ID NLM: 0372553
Informations de publication
Date de publication:
16 05 2022
16 05 2022
Historique:
received:
07
12
2021
revised:
28
01
2022
accepted:
04
03
2022
entrez:
16
5
2022
pubmed:
17
5
2022
medline:
20
5
2022
Statut:
ppublish
Résumé
Non-operative management of uncomplicated acute appendicitis is an option, but omission of antibiotics from the regimen has not been tested. A double-blind, placebo-controlled, superiority RCT in adults with CT-confirmed uncomplicated acute appendicitis was designed to compare placebo with antibiotics (intravenous ertapenem followed by oral levofloxacin and metronidazole). The primary endpoint was treatment success (resolution resulting in discharge without appendicectomy within 10 days); secondary outcomes included pain scores, complications, hospital stay, and return to work. From May 2017 to September 2020, 72 patients with a mean(s.d.) age of 37.5 (11.1) years were recruited at five hospitals. Six were excluded after randomization (5 early consent withdrawals, 1 randomization protocol violation), 35 were assigned to receive antibiotics, and 31 to receive placebo. Enrolment challenges (including hospital pharmacy resources in an acute-care surgery setting) meant that only the lowest sample size of three predefined scenarios was achieved. The 10-day treatment success rate was 87 (95 per cent c.i. 75 to 99) per cent for placebo and 97 (92 to 100) per cent for antibiotics. This clinical difference of 10 (90 per cent c.i. -0.9 to 21) per cent was not statistically different for the primary outcome (1-sided P = 0.142), and secondary outcomes were similar. The lack of antibiotic superiority statistically suggests that a non-inferiority trial against placebo is warranted in adults with CT-confirmed mild appendicitis. Registration number: EudraCT 2015-003634-26 (https://eudract.ema.europa.eu/eudract-web/index.faces), NCT03234296 (http://www.clinicaltrials.gov). Appendicitis was the most common reason for emergency surgery, but we now know that mild and severe acute appendicitis are two different diseases. Severe appendicitis still necessitates removal of the appendix but antibiotics alone are an option for mild disease. This small study found that most cases of mild appendicitis to resolve even without antibiotics. Larger studies (more patients) would be needed to show that omitting antibiotics is safe and no worse than antibiotic therapy for milder acute appendicitis.
Sections du résumé
BACKGROUND
Non-operative management of uncomplicated acute appendicitis is an option, but omission of antibiotics from the regimen has not been tested.
METHODS
A double-blind, placebo-controlled, superiority RCT in adults with CT-confirmed uncomplicated acute appendicitis was designed to compare placebo with antibiotics (intravenous ertapenem followed by oral levofloxacin and metronidazole). The primary endpoint was treatment success (resolution resulting in discharge without appendicectomy within 10 days); secondary outcomes included pain scores, complications, hospital stay, and return to work.
RESULTS
From May 2017 to September 2020, 72 patients with a mean(s.d.) age of 37.5 (11.1) years were recruited at five hospitals. Six were excluded after randomization (5 early consent withdrawals, 1 randomization protocol violation), 35 were assigned to receive antibiotics, and 31 to receive placebo. Enrolment challenges (including hospital pharmacy resources in an acute-care surgery setting) meant that only the lowest sample size of three predefined scenarios was achieved. The 10-day treatment success rate was 87 (95 per cent c.i. 75 to 99) per cent for placebo and 97 (92 to 100) per cent for antibiotics. This clinical difference of 10 (90 per cent c.i. -0.9 to 21) per cent was not statistically different for the primary outcome (1-sided P = 0.142), and secondary outcomes were similar.
CONCLUSION
The lack of antibiotic superiority statistically suggests that a non-inferiority trial against placebo is warranted in adults with CT-confirmed mild appendicitis. Registration number: EudraCT 2015-003634-26 (https://eudract.ema.europa.eu/eudract-web/index.faces), NCT03234296 (http://www.clinicaltrials.gov).
Appendicitis was the most common reason for emergency surgery, but we now know that mild and severe acute appendicitis are two different diseases. Severe appendicitis still necessitates removal of the appendix but antibiotics alone are an option for mild disease. This small study found that most cases of mild appendicitis to resolve even without antibiotics. Larger studies (more patients) would be needed to show that omitting antibiotics is safe and no worse than antibiotic therapy for milder acute appendicitis.
Autres résumés
Type: plain-language-summary
(eng)
Appendicitis was the most common reason for emergency surgery, but we now know that mild and severe acute appendicitis are two different diseases. Severe appendicitis still necessitates removal of the appendix but antibiotics alone are an option for mild disease. This small study found that most cases of mild appendicitis to resolve even without antibiotics. Larger studies (more patients) would be needed to show that omitting antibiotics is safe and no worse than antibiotic therapy for milder acute appendicitis.
Identifiants
pubmed: 35576384
pii: 6586451
doi: 10.1093/bjs/znac086
pmc: PMC10364767
doi:
Substances chimiques
Anti-Bacterial Agents
0
Ertapenem
G32F6EID2H
Banques de données
ClinicalTrials.gov
['NCT03234296']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
503-509Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
JAMA. 2021 Jan 26;325(4):351-352
pubmed: 33427858
N Engl J Med. 2020 Nov 12;383(20):1907-1919
pubmed: 33017106
Ann Surg. 2019 Dec;270(6):1028-1040
pubmed: 30720508
Br J Surg. 2017 Dec;104(13):1785-1790
pubmed: 28925502
JAMA. 2021 Jan 26;325(4):353-362
pubmed: 33427870
JAMA Surg. 2022 Mar 01;157(3):e216900
pubmed: 35019975
Br J Surg. 2018 Jul;105(8):933-945
pubmed: 29902346
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Br J Surg. 2012 Apr;99(4):532-9
pubmed: 22290281
N Engl J Med. 2020 Nov 26;383(22):2182-2184
pubmed: 33196154
JAMA. 2020 Aug 11;324(6):581-593
pubmed: 32730561
N Engl J Med. 2020 Feb 6;382(6):554-561
pubmed: 32023375
JAMA. 2015 Jun 16;313(23):2340-8
pubmed: 26080338
JAMA Surg. 2019 Mar 1;154(3):200-207
pubmed: 30484824
Ann Surg. 2021 Aug 1;274(2):240-247
pubmed: 33534226
JAMA Surg. 2021 Dec 1;156(12):1179-1181
pubmed: 34613361
JAMA. 2018 Sep 25;320(12):1259-1265
pubmed: 30264120
Scand J Surg. 2021 Jun;110(2):170-179
pubmed: 33851877
Lancet. 2011 May 7;377(9777):1573-9
pubmed: 21550483
Dis Colon Rectum. 2016 Jun;59(6):529-34
pubmed: 27145310
Arch Surg. 2011 Mar;146(3):308-14
pubmed: 21422362
Br J Surg. 2017 Jan;104(1):52-61
pubmed: 27686365
Scand J Surg. 2021 Jun;110(2):180-186
pubmed: 33934672
BMJ Open. 2018 Nov 3;8(11):e023623
pubmed: 30391919
JAMA Surg. 2020 Apr 1;155(4):283-289
pubmed: 32074268
Br J Surg. 2020 Jul;107(8):1062-1069
pubmed: 32073652
Surg Endosc. 2014 Mar;28(3):961-6
pubmed: 24178863